EnsoData is a startup that utilizes artificial intelligence to analyze the human body to diagnose health conditions. EnsoData, whose software uses machine learning algorithms to help clinicians score sleep data and diagnose patients with sleep apnea and other disorders, has now realized that dream—and then some. EnsoData's autoscoring algorithm combines AASM scoring best practices with cutting edge machine learning algorithms that learn and adapt to every single patient.
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.
EnsoData is a startup that utilizes artificial intelligence to analyze the human body to diagnose health conditions. EnsoData, whose software uses machine learning algorithms to help clinicians score sleep data and diagnose patients with sleep apnea and other disorders, has now realized that dream—and then some. EnsoData's autoscoring algorithm combines AASM scoring best practices with cutting edge machine learning algorithms that learn and adapt to every single patient.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
Eximis Surgical is developing an enabling technology that allows surgeons to quickly remove large specimens through small incisions. Its technology uses RF energized cutting wires temporarily held in place within a containment bag. It was founded in 2014 and headquartered in Louisville, Colorado.
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VR simulation, enabling users to get cost-effective and richer content experience.
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections.
SkySpecs was founded on 2012 and is based in Ann Arbor, Michigan.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
Eximis Surgical is developing an enabling technology that allows surgeons to quickly remove large specimens through small incisions. Its technology uses RF energized cutting wires temporarily held in place within a containment bag. It was founded in 2014 and headquartered in Louisville, Colorado.
Invenra Inc. is a biopharmaceutical company specializing in the discovery of biologics, particularly antibodies and their derivatives. Founded in 2011 and located in Madison, Wisconsin, Invenra utilizes a proprietary technology that integrates cell-free expression of full-length antibodies with extreme miniaturization. This innovative approach allows for the screening of a vast number of full-length antibodies in phenotypic assays, facilitating the identification of next-generation biologics. The company boasts a strong scientific foundation and a team of experts with extensive knowledge in genomics, biochemistry, and bioengineering, blending advanced basic research with practical commercial applications.
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections.
SkySpecs was founded on 2012 and is based in Ann Arbor, Michigan.
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
Elucent Medical LLC is focused on enhancing breast cancer treatment through innovative solutions. Founded in 2014 and headquartered in Brookfield, Wisconsin, the company develops and commercializes a wireless marker tag and detection system designed to locate breast abnormalities during surgical excision. By improving the accuracy and efficiency of these procedures, Elucent Medical aims to elevate the quality of care while simultaneously lowering costs, making treatments more accessible and affordable for both healthcare providers and patients. The company leverages the expertise of entrepreneurs from medicine, technology, and business to bring forward effective healthcare innovations.
Madison Vaccines, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing therapeutic plasmid DNA vaccines for prostate cancer and its associated bone metastases. Founded by Douglas McNeel, M.D., Ph.D., and Richard Lesniewski, Ph.D., the company is working on two primary vaccines: pTVG-HP and pTVG-AR. The lead vaccine, pTVG-HP, is administered via intradermal injection and targets prostatic acid phosphatase (PAP), with ongoing Phase 2 clinical trials for men at high risk of developing bone metastases following prostate cancer treatment. Initial trials have shown promising biological and biochemical activity. The second vaccine, pTVG-AR, aims to target the androgen receptor, a key driver of prostate cancer growth, and is expected to enter clinical trials soon. Additionally, Madison Vaccines is developing a companion diagnostic test based on a novel blood signature identified by the McNeel lab, which could help predict patient responses to these vaccines.
TAI Diagnostics, Inc. is a biotechnology company based in Wauwatosa, Wisconsin, specializing in non-invasive diagnostic tests for monitoring the health of transplanted organs in patients who have received solid organ transplants. Founded in 2013, the company focuses on utilizing cell-free DNA technology to enhance transplant surveillance, aiming to improve patient outcomes through highly sensitive diagnostic solutions. TAI Diagnostics is situated in the Milwaukee County Research Park, close to notable medical research institutions, which supports its mission to advance the field of organ transplant monitoring.
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections.
SkySpecs was founded on 2012 and is based in Ann Arbor, Michigan.
TAI Diagnostics, Inc. is a biotechnology company based in Wauwatosa, Wisconsin, specializing in non-invasive diagnostic tests for monitoring the health of transplanted organs in patients who have received solid organ transplants. Founded in 2013, the company focuses on utilizing cell-free DNA technology to enhance transplant surveillance, aiming to improve patient outcomes through highly sensitive diagnostic solutions. TAI Diagnostics is situated in the Milwaukee County Research Park, close to notable medical research institutions, which supports its mission to advance the field of organ transplant monitoring.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.
ReShape Medical Inc. is a medical device company specializing in non-surgical weight loss solutions for individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30-40. The company offers the ReShape procedure, which utilizes a dual intragastric balloon system combined with a personalized one-year weight loss program, aimed at facilitating weight loss through lifestyle changes. This procedure is designed for adult patients who have not achieved success with diet and exercise alone. ReShape Medical operates through medical weight loss centers and is based in San Clemente, California. Originally founded as Abdominis, Inc. in 2005, the company was rebranded and operates as a subsidiary of ReShape Lifesciences Inc. The broader product portfolio of its parent company includes other minimally invasive devices for treating obesity and metabolic diseases.
Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
Madison Vaccines, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing therapeutic plasmid DNA vaccines for prostate cancer and its associated bone metastases. Founded by Douglas McNeel, M.D., Ph.D., and Richard Lesniewski, Ph.D., the company is working on two primary vaccines: pTVG-HP and pTVG-AR. The lead vaccine, pTVG-HP, is administered via intradermal injection and targets prostatic acid phosphatase (PAP), with ongoing Phase 2 clinical trials for men at high risk of developing bone metastases following prostate cancer treatment. Initial trials have shown promising biological and biochemical activity. The second vaccine, pTVG-AR, aims to target the androgen receptor, a key driver of prostate cancer growth, and is expected to enter clinical trials soon. Additionally, Madison Vaccines is developing a companion diagnostic test based on a novel blood signature identified by the McNeel lab, which could help predict patient responses to these vaccines.
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Thalchemy Corp. develops neurally-inspired algorithms and accelerators aimed at continuous sensory processing in smartphones and other battery-operated devices. By mimicking the functionality of the mammalian thalamus, the company's technology allows for the routing, filtering, and preprocessing of sensory data, which enhances the detection of complex gestures and hot words across multiple modalities. This innovative approach significantly extends battery life for devices such as smartphones and wearables, while providing optimized voice and gesture control. Thalchemy's solutions also support the creation of always-on applications, simplifying development through an automated, user-friendly interface. Additionally, the technology can monitor environmental conditions, enabling applications that alert users or caregivers in emergency situations, such as falls or irregular heartbeats. Founded in 2012 and based in Madison, Wisconsin, Thalchemy aims to transform user interfaces and experiences across a variety of sensing platforms.
Prevacept Infection Control is a clinical-stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters.
Thalchemy Corp. develops neurally-inspired algorithms and accelerators aimed at continuous sensory processing in smartphones and other battery-operated devices. By mimicking the functionality of the mammalian thalamus, the company's technology allows for the routing, filtering, and preprocessing of sensory data, which enhances the detection of complex gestures and hot words across multiple modalities. This innovative approach significantly extends battery life for devices such as smartphones and wearables, while providing optimized voice and gesture control. Thalchemy's solutions also support the creation of always-on applications, simplifying development through an automated, user-friendly interface. Additionally, the technology can monitor environmental conditions, enabling applications that alert users or caregivers in emergency situations, such as falls or irregular heartbeats. Founded in 2012 and based in Madison, Wisconsin, Thalchemy aims to transform user interfaces and experiences across a variety of sensing platforms.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, dedicated to developing novel compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. In addition, Aerpio is developing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is currently in a Phase 1b clinical trial for inflammatory bowel disease. The company is also working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema. Aerpio has partnered with Quantum Leap Healthcare Collaborative to assess razuprotafib's efficacy in treating acute respiratory distress syndrome in patients with moderate to severe COVID-19. Founded in 2011, Aerpio Pharmaceuticals emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced approach to pharmaceutical development.
Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..
NeuMoDx Molecular, Inc. is a molecular diagnostics company focused on developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. Established in 2012 and based in Ann Arbor, Michigan, the company was formerly known as Molecular Systems Corporation before rebranding in April 2013. As of September 2020, NeuMoDx operates as a subsidiary of QIAGEN N.V. Its innovative products aim to enhance the efficiency and accuracy of molecular testing, contributing to better patient outcomes in various healthcare settings.
UpTo is a modern calendar that gives a more complete view of everything coming up that matters without the clutter. It creates a beautiful web calendar for their business or organization. The platform brings calendar to life and allows them to easily add events, without an IT department. Add events through an online account and watch them sync seamlessly across UpTo's mobile app and web calendars.
Upto was established in 2011 and is based in Detroit, Michigan, United States.
Madison Vaccines, Inc. is a biopharmaceutical company based in Madison, Wisconsin, focused on developing therapeutic plasmid DNA vaccines for prostate cancer and its associated bone metastases. Founded by Douglas McNeel, M.D., Ph.D., and Richard Lesniewski, Ph.D., the company is working on two primary vaccines: pTVG-HP and pTVG-AR. The lead vaccine, pTVG-HP, is administered via intradermal injection and targets prostatic acid phosphatase (PAP), with ongoing Phase 2 clinical trials for men at high risk of developing bone metastases following prostate cancer treatment. Initial trials have shown promising biological and biochemical activity. The second vaccine, pTVG-AR, aims to target the androgen receptor, a key driver of prostate cancer growth, and is expected to enter clinical trials soon. Additionally, Madison Vaccines is developing a companion diagnostic test based on a novel blood signature identified by the McNeel lab, which could help predict patient responses to these vaccines.
Cellectar Biosciences is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of cancer therapies. The company’s lead candidate, CLR 131, is currently undergoing Phase II clinical trials for patients with relapsed or refractory multiple myeloma and various B-cell malignancies, alongside a Phase I study for the same indications. Cellectar is also advancing CLR 1900, a phospholipid drug conjugate chemotherapeutic program aimed at solid tumors. In addition, the company collaborates with several partners, including Pierre Fabre and Avicenna Oncology, to develop various PDC programs. Originally founded in 2002 and known as Novelos Therapeutics until its rebranding in 2014, Cellectar Biosciences has its headquarters in Florham Park, New Jersey, and is recognized for its innovative approach to combining lipid-like molecules and phospholipid ethers with radioisotopes for cancer treatment and imaging.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, dedicated to developing novel compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. In addition, Aerpio is developing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is currently in a Phase 1b clinical trial for inflammatory bowel disease. The company is also working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema. Aerpio has partnered with Quantum Leap Healthcare Collaborative to assess razuprotafib's efficacy in treating acute respiratory distress syndrome in patients with moderate to severe COVID-19. Founded in 2011, Aerpio Pharmaceuticals emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced approach to pharmaceutical development.
Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, dedicated to developing novel compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. In addition, Aerpio is developing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is currently in a Phase 1b clinical trial for inflammatory bowel disease. The company is also working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema. Aerpio has partnered with Quantum Leap Healthcare Collaborative to assess razuprotafib's efficacy in treating acute respiratory distress syndrome in patients with moderate to severe COVID-19. Founded in 2011, Aerpio Pharmaceuticals emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced approach to pharmaceutical development.
Tissue Regeneration Systems Inc. is a start-up medical device company focused on skeletal reconstruction and bone regeneration technologies, licensed from the Universities of Michigan and Wisconsin. Established in 2005 and headquartered in Plymouth, Michigan, with a research facility in Ann Arbor and an additional office in Kirkland, Washington, the company targets applications in craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and bone growth factor delivery. Its technology has undergone extensive evaluation in large animal studies, yielding promising long-term results. The company has developed initial product offerings, completed necessary bench and animal testing, and submitted its first regulatory filings to the FDA. Successful approval of these submissions will facilitate the commercialization of its products in the United States, with expectations to generate significant revenue within the next two to three years.
Don’t let plans with friends slip through the cracks!
Nextt is a private network for close friends to connect online so they can do more together offline. Nextt simplifies the social planning process, letting you share ideas with friends and iron out the details (the Who, What, When and Where) in private. Use Nextt to get busy living and make quality time with your face-to-face friends a priority again.
UpTo is a modern calendar that gives a more complete view of everything coming up that matters without the clutter. It creates a beautiful web calendar for their business or organization. The platform brings calendar to life and allows them to easily add events, without an IT department. Add events through an online account and watch them sync seamlessly across UpTo's mobile app and web calendars.
Upto was established in 2011 and is based in Detroit, Michigan, United States.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
Netsocket specializes in virtualized, software-defined networking. The company’s flagship Netsocket Virtual Network (NVN) fulfills the promises of SDN and NFV today with powerful, robust automation applications running on a completely virtualized network infrastructure. It was founded in 2006 and headquartered in Plano, Texas.
BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform.
The company was originally founded as NanoBio Corporation, a spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation and NIH contracts, the company underwent a strategic “pivot” in 2016–17 to refocus its nanotechnology platform on the development of intranasal vaccines for respiratory and sexually transmitted diseases.
ReShape Medical Inc. is a medical device company specializing in non-surgical weight loss solutions for individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30-40. The company offers the ReShape procedure, which utilizes a dual intragastric balloon system combined with a personalized one-year weight loss program, aimed at facilitating weight loss through lifestyle changes. This procedure is designed for adult patients who have not achieved success with diet and exercise alone. ReShape Medical operates through medical weight loss centers and is based in San Clemente, California. Originally founded as Abdominis, Inc. in 2005, the company was rebranded and operates as a subsidiary of ReShape Lifesciences Inc. The broader product portfolio of its parent company includes other minimally invasive devices for treating obesity and metabolic diseases.
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, dedicated to developing novel compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. In addition, Aerpio is developing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is currently in a Phase 1b clinical trial for inflammatory bowel disease. The company is also working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema. Aerpio has partnered with Quantum Leap Healthcare Collaborative to assess razuprotafib's efficacy in treating acute respiratory distress syndrome in patients with moderate to severe COVID-19. Founded in 2011, Aerpio Pharmaceuticals emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced approach to pharmaceutical development.
Juventas Therapeutics, Inc., a clinical stage biotechnology company, develops non-viral gene therapies that activate natural processes to repair the body. The company focuses on treatment of non-healing wounds in patients with advanced peripheral artery disease. It offers JVS-100, a non-viral gene therapy that expresses stromal cell-derived factor-1 or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a range of disease states. Juventas Therapeutics, Inc. was formerly known as AcelleRX Therapeutics, Inc. and changed its name to Juventas Therapeutics, Inc. in April 2009. The company was founded in 2007 and is based in Cleveland, Ohio.
Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, dedicated to developing novel compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. In addition, Aerpio is developing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is currently in a Phase 1b clinical trial for inflammatory bowel disease. The company is also working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema. Aerpio has partnered with Quantum Leap Healthcare Collaborative to assess razuprotafib's efficacy in treating acute respiratory distress syndrome in patients with moderate to severe COVID-19. Founded in 2011, Aerpio Pharmaceuticals emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced approach to pharmaceutical development.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
Euthymics Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for central nervous system disorders. Established in 2009, the company aims to address significant unmet medical needs in areas such as major depressive disorder and alcohol use disorder. Euthymics is developing EB-1010, a therapeutic designed to enhance treatment efficacy for patients who do not respond adequately to standard antidepressants, while minimizing common side effects like weight gain and cognitive impairment. Additionally, the company is working on therapies to assist individuals with withdrawal symptoms, impulsivity, and cravings associated with alcohol use and smoking cessation. Euthymics' research is particularly relevant given the high prevalence of these conditions, affecting millions of Americans.
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine to protect against dengue fever, a disease that threatens 2.5 billion people across the globe. Inviragen is also developing a vaccine to protect against West Nile for the North American market, a nasal combination vaccine to protect against both plague and smallpox for biodefense, and a unique vaccine to protect against avian influenza for global markets.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform.
The company was originally founded as NanoBio Corporation, a spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation and NIH contracts, the company underwent a strategic “pivot” in 2016–17 to refocus its nanotechnology platform on the development of intranasal vaccines for respiratory and sexually transmitted diseases.
ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.
LensX Lasers is a maker of surgical lasers used to repair cataracts.
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Tissue Regeneration Systems Inc. is a start-up medical device company focused on skeletal reconstruction and bone regeneration technologies, licensed from the Universities of Michigan and Wisconsin. Established in 2005 and headquartered in Plymouth, Michigan, with a research facility in Ann Arbor and an additional office in Kirkland, Washington, the company targets applications in craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and bone growth factor delivery. Its technology has undergone extensive evaluation in large animal studies, yielding promising long-term results. The company has developed initial product offerings, completed necessary bench and animal testing, and submitted its first regulatory filings to the FDA. Successful approval of these submissions will facilitate the commercialization of its products in the United States, with expectations to generate significant revenue within the next two to three years.
At Nerites, they combine world class technology with a management team that has a proven track record of bringing technical innovation to market. The company was founded in 2004 to commercialize a new generation of synthetic biomaterials that can enhance natural tissue repair, reduce complications from traditional devices, and degrade safely when they are no longer needed.
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
Pattern Insight brings powerful search and data mining technology to the advanced, real-time analysis of every type of engineering and IT data. Pattern Insight have two products. Log Insight is a Big Data analytics and log management platform for analyzing large amounts of machine-generated data in real time. It is used for operational analytics in traditional data center and cloud environments. Log Insight, together with its team and technology has been acquired by VMware in July 2012. Code Insight is a product that identifies and removes all ‘known’ (previously fixed) defects in source code before it is released. Current customers include Cisco, Intel, Qualcomm, Tellabs and Motorola.
Cellectar Biosciences is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of cancer therapies. The company’s lead candidate, CLR 131, is currently undergoing Phase II clinical trials for patients with relapsed or refractory multiple myeloma and various B-cell malignancies, alongside a Phase I study for the same indications. Cellectar is also advancing CLR 1900, a phospholipid drug conjugate chemotherapeutic program aimed at solid tumors. In addition, the company collaborates with several partners, including Pierre Fabre and Avicenna Oncology, to develop various PDC programs. Originally founded in 2002 and known as Novelos Therapeutics until its rebranding in 2014, Cellectar Biosciences has its headquarters in Florham Park, New Jersey, and is recognized for its innovative approach to combining lipid-like molecules and phospholipid ethers with radioisotopes for cancer treatment and imaging.
Deltanoid Pharmaceuticals is a biopharmaceutical company based in Madison, Wisconsin, focused on the research, development, and commercialization of therapies for various human diseases, including renal diseases, osteoporosis, and skin conditions. Founded in 1999, the company initially aimed to advance university inventions, particularly vitamin D analogs and other compounds licensed from the Wisconsin Alumni Research Foundation. Deltanoid's notable products include DP001, which targets secondary hyperparathyroidism in patients with chronic kidney disease undergoing hemodialysis, and DP006 for acne treatment. The company is dedicated to developing selected therapies through the early phases of drug development and actively seeks partnerships for later-stage development and commercialization. Currently, Deltanoid has a partnership with Novadiol, Inc. for the development of a vitamin D therapy.
Virent Energy Systems, Inc. is an energy technology company based in Madison, Wisconsin, specializing in the production of hydrocarbon chemicals and fuels from plant sugars. Utilizing its patented BioForming technology, Virent converts various bio-based feedstocks, such as beet sugar, sugar cane, corn starch, and cellulosic materials like bagasse and corn stover, into products that are chemically identical to petroleum-derived fuels and chemicals. The company’s offerings include gasoline, diesel, jet fuel, and bio-aromatic compounds used in a variety of applications, such as paints, textiles, and automotive products. Virent has established strategic partnerships with notable companies, including Royal Dutch Shell and The Coca-Cola Company, to further its mission of providing renewable alternatives to fossil fuels. Founded in 2002, Virent operates as a subsidiary of Marathon Petroleum Corporation.
ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.
Incept BioSystems develops innovative microscale technologies that provide fertility specialists breakthrough capabilities to treat infertility. Our technologies improve the in vitro manipulation, performance, and viability of high-value cells, and our mission is to set the standard for next-generation clinical devices for the Assisted Reproductive Technology (ART) laboratory. Like many specialized cells, human embryos typically behave much differently while in vitro than they would in the body, and this performance gap can limit their developmental growth and potentially their viability. Incept’s System for Microfluidic Assisted Reproductive Technology (SMART) platform is the first to deliver unique control of in vitro cell culture environments so that fertility specialists can offer patients new hope in starting a family.
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.
Virent Energy Systems, Inc. is an energy technology company based in Madison, Wisconsin, specializing in the production of hydrocarbon chemicals and fuels from plant sugars. Utilizing its patented BioForming technology, Virent converts various bio-based feedstocks, such as beet sugar, sugar cane, corn starch, and cellulosic materials like bagasse and corn stover, into products that are chemically identical to petroleum-derived fuels and chemicals. The company’s offerings include gasoline, diesel, jet fuel, and bio-aromatic compounds used in a variety of applications, such as paints, textiles, and automotive products. Virent has established strategic partnerships with notable companies, including Royal Dutch Shell and The Coca-Cola Company, to further its mission of providing renewable alternatives to fossil fuels. Founded in 2002, Virent operates as a subsidiary of Marathon Petroleum Corporation.
Chromatin is a biotechnology company focused on developing and marketing innovative agricultural products, particularly hybrid, drought-tolerant sorghum seeds. By utilizing advanced breeding methodologies and combining diverse sorghum varieties, Chromatin aims to meet the growing demand for sustainable agricultural systems. Its products are designed to thrive in various climates, making them suitable for cultivation on over 80% of the world's agricultural land. This versatility enables farmers to optimize crop production for both traditional agricultural markets and bio-industrial applications, which include the creation of renewable chemicals, materials, and fuels. Through these efforts, Chromatin addresses key societal challenges related to agricultural productivity and renewable energy resources.
ZyStor Therapeutics, Inc. is a privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal storage diseases.
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Chromatin is a biotechnology company focused on developing and marketing innovative agricultural products, particularly hybrid, drought-tolerant sorghum seeds. By utilizing advanced breeding methodologies and combining diverse sorghum varieties, Chromatin aims to meet the growing demand for sustainable agricultural systems. Its products are designed to thrive in various climates, making them suitable for cultivation on over 80% of the world's agricultural land. This versatility enables farmers to optimize crop production for both traditional agricultural markets and bio-industrial applications, which include the creation of renewable chemicals, materials, and fuels. Through these efforts, Chromatin addresses key societal challenges related to agricultural productivity and renewable energy resources.
Intersymbol Communications, Inc. develops and manufactures high-speed physical layer components for next generation broadband networking systems. Intersymbol's innovative products enhance the bandwidth and reach while simultaneously reducing the power consumption of broadband networks. This results in a dramatic reduction in deployment cost for next generation network providers.
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Corona Optical Systems is a Midwest-based high-technology company with headquarters in Lombard, Illinois. Additional facilities are located in Eau Claire, Wisconsin and San Jose, California. Corona's key technologies focus on high-speed optoelectronic components and subsystems for carrier-class equipment. Founded in February 2000, Corona is a privately held, venture capital funded corporation. Following an initial angel round, Corona completed its first institutional investment round in March 2001. Funds raised in this Series A round totaled $12.4 Million. Led by Intel Capital, this round included Chicago based venture capital firm KB Partners, Madison, Wisconsin based Venture Investors and the Geometry Group of New York City.
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.
SoftSwitching Technologies offer the most affordable, effective and scalable power quality and monitoring solutions available on the market. A full array of scalable, battery-free DySC products. I-Sense intelligent sensors that pinpoint time and duration of voltage sags. And Grid Alert™ event notifications—the only global power reporting and notification network in the world.
Gala Biotech, a Catalent Pharma Solutions Company, was established in 1996 from technology developed at the University of Wisconsin. Located in Middleton, Wisconsin, this rapidly growing company (currently over 40 employees, including 16 PhD’s) has a wide range of capabilities in the fields of molecular biology, vector biology, cell line development, biopharmaceutical manufacturing, protein biochemistry, and quality systems. Gala’s core proprietary technology is GPEx® (Gene Product Expression), a gene insertion/expression technology that allows rapid creation of stable, high-expressing mammalian cell lines for a wide variety of gene products. "Gala" is Greek for milk, and the company's original mission was to produce pharmaceutical proteins in the milk of transgenic cows. The gene insertion technology that Gala developed to generate transgenic animals became the basis of Gala's Gene Product Expression or GPEx® technology for production of recombinant proteins in mammalian cell culture. The genomics revolution has led to the identification of thousands of new genes, and the race is now on to discover, characterize and stably express the protein products of these genes in order to develop new therapeutic proteins. Gala's GPEx® technology, when applied to mammalian cell culture, accelerates this process for its biopharmaceutical partners. Once new therapeutic proteins have been identified for clinical development, production support becomes a major challenge. Gala's mission is to meet this need, and the company has recently established a 43,000 square-foot facility in Middleton, Wisconsin devoted to GPEx®-based cell line development and cGMP-compliant protein production.
Alfalight designs and manufactures high-power diode lasers for the industrial, defense, and telecommunications markets. Alfalight's innovative technology is based on advanced aluminum-free active region (ALFA) laser structures, enabling the manufacture of laser diodes with exceptionally high reliability and industry-leading efficiency.
TomoTherapy develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy:registered: platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its Hi·Art:registered: treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD:tm: treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile:tm: relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. As of February 2011, there are more than 350 TomoTherapy systems in use in 24 countries worldwide. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
Third Wave Technologies, Inc. engages in the development and marketing of molecular diagnostic products for various DNA and RNA analysis applications. It provides physicians and researchers with molecular solutions for the analysis and treatment of disease. The company offers products based proprietary Invader chemistry, a technology used in women's health, infectious disease, genetics and pharmacogenetics, and oncology segments. Third Wave principally offers inVitro diagnostic devices and analyte specific reagents. The company's analyte specific reagents allow laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing, and a host of other mutations associated with genetic predispositions and other diseases. Third Wave also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Third Wave sells its products through a combination of direct sales personnel who focuses primarily on the clinical market, as well as through collaborative relationships in the United States and Europe. The company was founded in 1993 and is headquartered in Madison, Wisconsin. As of July 23, 2008, Third Wave Technologies Inc. operates as a subsidiary of Hologic Inc.
Promega Corporation, founded in 1978 and based in Madison, Wisconsin, specializes in manufacturing reagents and instrumentation for research, pharmaceutical, and diagnostics laboratories. The company offers over 2,000 products that support various applications, including cell biology, nucleic acid analysis, protein analysis, and molecular diagnostics. Its solutions are utilized in fields such as drug discovery, clinical research, forensic analysis, and human identification. In addition to standard products, Promega provides custom manufacturing, assay development, automation solutions, and quality control services. The company distributes its products globally through a network of distributors, reflecting its commitment to advancing scientific research and medical diagnostics.